Skip to main content
OpenTrials
Completed

NCT Number: NCT04264962

Yang Yin Fu Zheng Jie Du Therapy in Recurrence of Hepatocellular Carcinoma Less Than 3 cm in Diameter

Clinical research of Yang Yin Fu Zheng Jie Du therapy in recurrence of Hepatocellular Carcinoma less than 3 cm in diameter.The purpose of this study is to observe the efficacy of routine medical care combined with Yang Yin Fu Zheng Jie Du therapy in 1 year recurrence for patients belong to Hepatocellular Carcinoma less than 3 cm in diameter.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hepatocellular Carcinoma Adenocarcinoma Carcinoma Carcinoma, Hepatocellular Digestive System Diseases Digestive System Neoplasms Liver Diseases Liver Neoplasms Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Glandular and Epithelial

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Early Phase 1

Primary location

Zhiyun Yang

Beijing, Beijing Municipality, 100015, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Meet the criteria of hepatocellular carcinoma
  • Ages Eligible for Study: ≤75 years old;
  • The size of the main nodule and multi-centricity (single lesion, three nodules ≤3 cm)
  • After transarterial chemoembolisation (TACE) or radiofrequency ablation (RFA)
  • Surgery cannot be allowed;
  • Informed consent from the patient.

Exclusion criteria

  • Serious problem of heart, lung, or kidney with severe dysfunction;
  • Pregnant or child breast feeding women;
  • Mental or cognitive disorders;
  • Participating in other drug trials;
  • Who are allergic to the study drug.

Treatment and study plan

Yang Yin Fu Zheng Jie Du therapy

Drug

Yang Yin Fu Zheng Jie Du is a Chinese herbal compound.

Routine medical care

Other

Routine medical care

Primary outcomes

  1. Recurrance rate

    Time frame: 1 year

Secondary outcomes

  1. Objective response rate

    Time frame: 1 year

  2. quality of life (QOL) questionnaire

    Time frame: 1 year

Sponsors and collaborators

Lead sponsor

Beijing Ditan Hospital

Other

Collaborators

  • Xiyuan Hospital of China Academy of Chinese Medical Sciences

Registry information

Acronym: YYFZJDTRHCLT3D

Important dates

Study start
2017
Primary completion
2021
Study completion
2021
First posted
Feb 11, 2020
Registry last updated
Oct 12, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.